Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24

Viking Therapeutics, Inc.

2023-FY EPS reported -$0.91

Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.
Cash & equivalents $362.1M vs $155.5M year-end 2022, funding pipeline milestones.
Phase 2 VENTURE (VK2735, obesity) topline results expected in 1Q24; oral VK2735 Phase 1 data also 1Q24.
Phase 2b VOYAGE (VK2809, NASH) 52-week histology results expected in 1H24.
Phase 1b VK0214 for X-ALD results expected in 1H24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viking Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.

View on SEC.gov

Browse all earnings releases →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-012199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.